Risperidone-associated Steatohepatitis and Excessive Weight-gain

Pharmacopsychiatry

Volumn 36, Issue 5, 2003, Pages 206-207

  Holtmann, M ^a   Kopf, D ^a   Mayer, M ^a   Bechtinger, E ^a   Schmidt, M H ^a  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CHOLESTEROL; CLOZAPINE; GLUCOSE; LEPTIN; LIPID; LIVER ENZYME; NEUROLEPTIC AGENT; NEUROPEPTIDE Y; RISPERIDONE; TRIACYLGLYCEROL;

ADOLESCENT; ARTICLE; BODY WEIGHT; CASE REPORT; CLINICAL TRIAL; DRUG EFFECT; FATTY LIVER; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; IATROGENIC DISEASE; LIPID BLOOD LEVEL; LIVER DISEASE; LIVER FUNCTION; LIVER TOXICITY; OBESITY; PARANOID PSYCHOSIS; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; SIDE EFFECT; STEATOHEPATITIS; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; FATTY LIVER; FEMALE; HUMANS; PARANOID DISORDERS; RISPERIDONE; WEIGHT GAIN;

EID: 0242351970     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-43045     Document Type: Article

References (10)

1. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001; 62 Suppl 7: 22-31
2. Angelucci F, Aloe L, Gruber SH, Fiore M, Mathe AA. Chronic antipsychotic treatment selectively alters nerve growth factor and neuropeptide Y immunoreactivity and the distribution of choline acetyl transferase in rat brain regions. Int J Neuropsychopharmacol 2000; 3(1): 3-25
3. Baptista T, Lacruz A, Angeles F, Silvera R, de Mendoza S, Mendoza MT, Hernandez L. Endocrine and metabolic abnormalities involved in obesity associated with typical antipsychotic drug administration. Pharmacopsychiatry 2001; 34(6): 23-31
4. Faggioni R, Jones-Carson J, Reed DA, Dinarello CA, Feingold KR, Grunfeld C, Fantuzzi G. Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: role of tumor necrosis factor alpha and IL-18. Proc Natl Acad Sci U S A 2000; 9(5): 367-72
5. Kumra S, Herion D, Jacobsen LK, Briguglia C, Grothe D. Case study: risperidone-induced hepatotoxicity in pediatric patients. J Am Acad Child Adolesc Psychiatry 1997; 36(5): 01-5
6. McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 2001; 46(3): 73-81
7. Szigethy E, Wiznitzer M, Branicky LA, Maxwell K, Findling RL. Risperidone-induced hepatotoxicity in children and adolescents? A chart review study. J Child Adolesc Psychopharmacol 1999; 9 (2): 3-8
8. Virkkunen M, Wahlbeck K, Rissanen A, Naukkarinen H, Franssila-Kallunki A. Decrease of energy expenditure causes weight increase in olanzapine treatment - a case study. Pharmacopsychiatry 2002; 35 (3): 24-6
9. Weiterung T. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 2001; 24(1): 9-73
10. Wieczorek I, Schulz C, Jarry H, Lehnert H. The effects of the selective serotonin reuptake-inhibitor fluvoxamine on body weight in Zucker rats are mediated ba corticotropin-releasing hormone. Int J Obes Relat Metab Disord 2001; 25(10): 566-9